ForecastQ
PortfoliosScreenerAbout
Screener > ZURA

ZURA

Zura Bio Limited
  • Healthcare
  • Biotechnology
  • $495M market cap
Forecast run · Sep 14, 2026Upside rank 153 of 3,136

Model Signal

ForecastQ Daily Probabilities
69.4%
38.8%
46.0%

Analyst Consensus

Recommendation2.00/5 Buy
Last price$5.21
Price target$20.00
Implied move+283.9%
Analysts8

ForecastQ Portfolios

ZURA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

ForecastQ

Quantitative stocks signals powered by AI

Portfolios·Screener·About

The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.

© ForecastQ. All rights reserved.